TRANSFAL

OFFICIAL TITLE: PROSPECTIVE EVALUATION OF PREDICTIVE/PROGNOSTIC BIOMARKERS FOR PALBOCICLIB AND ENDOCRINE THERAPY IN ER POSITIVE HER2 NEGATIVE ADVANCED METASTATIC BREAST CANCER WITHIN THE PARSIFAL CLINICAL TRIAL.

SABCS 2019 – DOWNLOAD THE POSTER

PROJECT DETAILS

THE TRANSFAL PROJECT IS A SUB-STUDY WITHIN THE PARSIFAL CLINICAL TRIAL. THE INITIAL GOAL WILL BE TO ANALYZE THE MOLECULAR TUMOR PROFILE AT THE TIME OF PROGRESSION IN PATIENTS WITH MODERATE SENSITIVITY TO PALBOCICLIB IN COMBINATION WITH FIRST-LINE ENDOCRINE THERAPY. FOR THIS PURPOSE, DIFFERENT MOLECULAR APPROACHES, SUCH AS DIFFERENTIAL PROTEOMICS, IN VIVO PDX MODELS, FISH, DNA SEQUENCING, WILL BE RUN ON AN INITIAL SUBSET OF THE PARSIFAL POPULATION.

TUMOR TYPE

PHASE

N

SITES

COUNTRY

STATUS

BREAST

Sub-study

280

52

Spain, France, Italy, UK, Germany, Czech Republic, Russia

Recruitment period finished